Immune response diagnostics for tomorrow‘s health
 
Hummingbird Diagnostics is developing patient-friendly and minimally invasive diagnostic tests for early disease detection, personalized medicine and health monitoring from blood samples and other liquid biopsies, such as serum, plasma, cerebrospinal fluid, urine and saliva.
Our mission is to unlock the power of blood-borne microRNAs to read the immune system’s response to disease, enhancing the potential for innovative disease screening, early & effective diagnostics, and patient-specific prognostics as well as monitoring of patient-centric therapies.
Hummingbird’s tests are based on the analysis of tiny disease-specific molecules, called microRNAs, that indicate the onset, progression and remission of disease. 
Our long-term goal is to detect serious and life-threatening conditions earlier, in a simpler, robust and more accurate fashion and improve clinical outcomes through earlier intervention. 
Hummingbird’s lead program for the early diagnosis of lung cancer from blood samples is in clinical validation at world-leading centers.